Check out today’s featured companies who have recently raised a round of funding, and be sure to check out the full list of past healthcare IT fundings.
RevealDx Announces Distribution Agreement and Investment from 4DMedical
4DMedical to Distribute RevealAI-Lung in the US, Europe, Australia, and New Zealand
RevealDx, a leader in AI characterization of lung nodules, announced today, following World Lung Cancer Day, a distribution agreement and strategic investment of $3.4 million by 4DMedical (ASX: 4DX), expanding access to its flagship product, RevealAI-Lung. RevealAI-Lung has received MDR Certification, TGA Approval, and FDA clearance. In the transaction with 4DMedical, Chestnut Partners, Inc. served as the exclusive financial advisor to RevealDx.
This news follows 4DMedical’s recent acquisition of Austrian-based Contextflow. 4DMedical, a global medical technology company, is revolutionising respiratory care through advanced imaging and artificial intelligence. Contextflow offers advanced chest CT technologies that automate the identification of lung nodules. RevealAI-Lung has been integrated into the Contextflow platform and is already operational at several clinical sites across Europe.
The RevealDx technology characterizes incidental lung nodules by producing a Malignancy Similarity Index (mSI), a score that helps radiologists make more informed follow-up recommendations to assist in cancer diagnosis. The company has validated the software on over 1,500 patients from a variety of cohorts.
The RevealAI-Lung CADx device offers several key capabilities, including:
- Significant improvement in Radiologist reader performance
- Use of real-world NLST data as our reference population
- Clinically relevant malignancy scoring
- First-ever integration directly into PACS, vastly improving workflow
- Proven generalizability across exam types and patient populations
“We are excited to announce our new partnership with 4DMedical,” said Chris Wood, CEO at RevealDx. “As we recognize World Lung Cancer Day, this milestone underscores our commitment to helping clinicians identify potentially malignant lung nodules earlier and with greater confidence. The incredible team at 4DMedical and the resources they bring will expand our reach and benefit patients.”
Andreas Fouras, Founder and CEO at 4DMedical, said, “For 4DMedical, this is about more than adding products. It is about building a connected ecosystem for cardiopulmonary care. CT:VQ gives physicians physiological insight into how the lung is actually functioning. By surrounding that capability with disease detection and AI-powered risk stratification, we can help health systems identify the right patients earlier and ensure they receive appropriate care. The result is a platform that has the potential to improve outcomes for patients while increasing utilization of advanced functional imaging across vital disease areas.”
In addition to its recent regulatory milestones, RevealAI-Lung is reimbursable by Medicare in the United States under CPT codes 0721T and 0722T, helping to support broader clinical adoption.
About RevealDx
RevealDx has developed RevealAI-Lung, the first Medical Imaging AI software to achieve reimbursement in both the US and EU. The company has published several studies demonstrating significant improvement in both early cancer detection as well as reduction in false positives. Studies show that by integrating this patented technology into routine clinical use, healthcare providers can more effectively triage lung nodules. For more information, contact sales@reveal-dx.com.
Learn more at reveal-dx.com
About 4DMedical
4DMedical Limited (ASX:4DX) is a global medical technology company revolutionising respiratory care with advanced imaging and artificial intelligence. Its patented XV Technology transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.
4DMedical’s expanding software portfolio includes the FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS), CT LVAS, and the ground-breaking CT:VQ solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.
Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical’s solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalised patient care. With the addition of advanced AI capabilities from its 2023 acquisition of Imbio and 2026 acquisition of contextflow, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.
Learn more at 4dmedical.com
Originally announced August 3rd, 2026.
Prosper Medical Raises $16M to Bring AI-powered Concierge Care to All
Prosper Medical today announced $16 million in financing to scale its AI-powered concierge primary care platform. The company was founded by Ryan McQuaid and James Wantuck, MD, who previously built and sold PlushCare, one of the country’s first direct-to-consumer telehealth platforms, for $450 million. Now they’re back, and they’re using AI to address one of healthcare’s most persistent challenges: delivering personalized, seamless primary care at scale.
While telemedicine made healthcare more convenient, McQuaid and Wantuck came away with a larger realization: convenience alone doesn’t solve the primary care crisis. The real problem is a trusted relationship. Most Americans don’t have a physician who knows them well, really listens to them, and cares about them. That kind of care has always existed, but for most people it’s been out of reach, and Prosper was built to change that.
“When we built PlushCare, we learned that making appointments easier wasn’t enough,” said Ryan McQuaid, Co-Founder and CEO at Prosper Medical. “The real challenge is everything that happens after a patient leaves the visit. Following up on test results, finding the right specialist, collecting comprehensive health data, and preventing major problems before they arise. AI finally gives us a way to deliver that level of care and personalization at a scale that wasn’t possible before.”
The goal isn’t to replace physicians, but to supercharge them in caring for their patients. Prosper’s platform maintains continuity across every patient interaction, aggregates all of your health data, coordinates care, and ensures important data signals and communication don’t get lost between appointments. The result is a Prosper doctor who arrives with context, Prosper AI that can intervene earlier, a Care Concierge Team, and a healthcare experience that feels far more personal than traditional primary care.
Unlike many concierge or membership-based healthcare services, Prosper is designed to be accessible to more than only the ultra-wealthy…
Full release here, originally announced July 23rd, 2026.
No comments:
Post a Comment